NCI/ADR-RES

NCI/ADR-RES
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	N/A
Complications	N/A
Onset	N/A
Duration	N/A
Types	N/A
Causes	N/A
Risks	N/A
Diagnosis	N/A
Differential diagnosis	N/A
Prevention	N/A
Treatment	N/A
Medication	N/A
Prognosis	N/A
Frequency	N/A
Deaths	N/A

NCI/ADR-RES is a cell line that is used in cancer research to study multidrug resistance. This cell line was originally derived from the ovarian cancer cell line OVCAR-8 and has been selected for resistance to the chemotherapy drug doxorubicin.

Characteristics

NCI/ADR-RES cells exhibit a phenotype that is resistant to a wide range of anticancer drugs, making them a valuable model for studying the mechanisms of drug resistance in cancer cells. These cells overexpress the P-glycoprotein (P-gp), which is encoded by the ABCB1 gene, also known as the MDR1 gene. P-glycoprotein acts as a drug efflux pump, reducing the intracellular concentration of drugs and thereby contributing to the multidrug resistance phenotype.

Research Applications

The NCI/ADR-RES cell line is widely used in oncology research to:

• Investigate the molecular mechanisms underlying drug resistance.
• Screen for new therapeutic agents that can overcome or bypass drug resistance.
• Study the role of gene expression and genetic mutations in the development of drug resistance.

See Also

• Multidrug resistance
• P-glycoprotein
• Cancer cell line
• Chemotherapy

External Links

• NCI/ADR-RES Cell Line Information